Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Impact And Reliability Of Pleural Fluid Mesothelin In Undiagnosed Pleural Effusions.

H. E. Davies, R. Sadler, S. Bielsa, N. Maskell, N. Rahman, R. Davies, B. Ferry, Y. Lee
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
RATIONALE Serum mesothelin is a new biomarker for the diagnosis of mesothelioma. Patients with mesothelioma commonly present with pleural effusions. To define the clinical utility of mesothelin quantification in pleural fluid, we assessed its additional value over pleural fluid cytology and its short-term reproducibility and reliability after pleural inflammatory processes, including pleurodesis. OBJECTIVES To assess the diagnostic role of pleural fluid mesothelin and the effect of common clinical factors that may influence measurement accuracy. METHODS Mesothelin was quantified in 424 pleural fluid and 64 serum samples by ELISA. Fluid was collected prospectively from 167 patients who presented with pleural effusions for investigation. Serial pleural fluid samples were obtained from patients (n = 33) requiring repeated drainage. Mesothelin levels were also measured in patients (n = 32) prepleurodesis and postpleurodesis. MEASUREMENTS AND MAIN RESULTS Pleural fluid mesothelin concentrations were significantly higher in patients with mesothelioma (n = 24) relative to those with metastatic carcinomas (n = 67) and benign effusions (n = 75): median (interquartile range, 25th-75th percentile) = 40.3 (18.3-68.1) versus 6.1 (1.5-13.2) versus 3.7 (0.0-12.4) nM, respectively, P < 0.0001. Mesothelin measurement was superior to cytological examination in the diagnosis and exclusion of mesothelioma (sensitivity, 71 vs. 35%; specificity, 89 vs. 100%; negative predictive value, 95 vs. 82%, respectively). In patients with "suspicious" cytology, pleural fluid mesothelin was 100% specific for mesothelioma, and in cytology-negative effusions (n = 105) offered a negative predictive value of 94%. Intraindividual reproducibility of pleural fluid mesothelin was excellent: mean (+/-SD) variation, -0.15 (+/-8.41) nM in samples collected within 7 days from patients with mesothelioma. Measurements remained reliable after pleurodesis and were not affected by the presence of bacteria. CONCLUSIONS Pleural fluid mesothelin provides additional diagnostic value relative to cytological examination. Mesothelin measurements are reproducible and not affected by inflammatory pleural processes.
This paper references
10.1136/thx.58.suppl_2.ii8
BTS guidelines for the investigation of a unilateral pleural effusion in adults
N. Maskell (2003)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1111/resp.13207_17
Clinical Respiratory Medicine
R. Albert (2004)
Textbook of Pleural Diseases, 2nd edition.
K. Ramar (2009)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
10.1186/1471-2407-8-194
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
L. Herszényi (2008)
10.1016/J.LUNGCAN.2005.03.002
Asbestos and mesothelioma: worldwide trends.
L. Kazan-Allen (2005)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
Pleural fluid mesothelin levels: diagnostic accuracy, reproducibility and reliabilityafterpleurodesis [abstract 48].Thorax 2008;63(SupplVII):S107
HE Davies (2008)
10.1164/AJRCCM.161.2.9904123
Talc induces apoptosis in human malignant mesothelioma cells in vitro.
N. Nasreen (2000)
10.1001/JAMA.1993.03500090059033
Prospective study of serum CA-125 levels as markers of ovarian cancer.
K. Helzlsouer (1993)
10.3348/kjr.2004.5.1.11
Receiver Operating Characteristic (ROC) Curve: Practical Review for Radiologists
S. Park (2004)
10.1089/HYB.1989.8.569
Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer.
E. M. Goldberg (1989)
10.2307/3342826
Exporting Asbestos: Disease and Policy in the Developing World
M. Huncharek (1993)
10.1002/(SICI)1097-0339(200001)22:1<7::AID-DC3>3.0.CO;2-U
Individual specimen triage of effusion samples: An improvement in the standard of practice, or a waste of resources?
A. Filie (2000)
Pathology: cytology
MR Wick (2008)
10.1148/RADIOLOGY.148.3.6878708
A method of comparing the areas under receiver operating characteristic curves derived from the same cases.
J. Hanley (1983)
10.1148/radiology.143.1.7063747
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
James A Hanley (1982)
10.1164/rccm.200801-062OC
Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.
N. Rahman (2008)
10.1016/S1556-0864(15)31535-5
Soluble Mesothelin Related Protein in Mesothelioma
J. Creaney (2006)
10.1016/J.LUNGCAN.2004.12.004
Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?
H. Carolan (2005)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1001/jama.294.1.66
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Ian M Thompson (2005)
10.1073/pnas.012669199
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice
J. Brown (2002)
10.1378/CHEST.122.3.1018
Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis.
J. Ferrer (2002)
Clinical Respiratory Medicine, 2nd ed (Albert RK, Spiro SG, Jett JR)
R. L. Coffey (2005)
Textbook of Pleural Diseases
R. Light (2008)
10.1016/J.CCM.2006.01.004
Management of malignant pleural mesothelioma.
S. West (2006)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1164/RCCM.200311-1579OC
Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size.
N. Maskell (2004)
The diagnostic accuracy and reproducibility of pleural fluid levels of mesothelin in unselected patients with pleural effusions [abstract 61
HE Davies (2008)
10.1001/JAMA.294.1.66
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
I. Thompson (2005)
10.1093/JJCO/29.11.550
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
T. Yamao (1999)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1164/AJRCCM-CONFERENCE.2009.179.1_MEETINGABSTRACTS.A3934
The Clinical Role and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions.
H. E. Davies (2009)
10.1136/pmj.78.925.646
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers
S. Jain (2002)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1016/j.lungcan.2005.03.002
Asbestos and mesothelioma: worldwide trends.
Laurie Kazan-Allen (2005)
10.1148/RADIOLOGY.143.1.7063747
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
J. Hanley (1982)
10.1016/S0002-9343(99)00217-X
Hepatic hydrothorax: pathogenesis, diagnosis, and management.
K. N. Lazaridis (1999)
Elimination of asbestos - related disease [ policy paper ]
IM Thompson
10.1136/thx.2006.076612
Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
Y. Lee (2007)
10.1002/DC.20200
The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma
L. Ylagan (2005)
10.1136/THORAX.2003.013094
BTS guidelines for the management of pleural infection.
C. Davies (2003)
10.7326/0003-4819-77-4-507
Pleural effusions: the diagnostic separation of transudates and exudates.
R. Light (1972)
Pleural fluid mesothelin levels : diagnostic accuracy , reproducibility and reliabilityafterpleurodesis [ abstract 48 ]
HE Davies (2008)



This paper is referenced by
10.1515/CCLM.2011.242
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
S. Yamada (2011)
10.1165/rcmb.2011-0182OC
Characterization of a new mouse model of empyema and the mechanisms of pleural invasion by Streptococcus pneumoniae.
S. Wilkosz (2012)
10.1002/dc.21303
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1007/s12032-012-0422-6
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
10.1097/CPM.0B013E318285BA37
The Art of Pleural Fluid Analysis
S. Sahn (2013)
10.1007/s12032-013-0543-6
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
R. Filiberti (2013)
10.21873/anticanres.13719
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
Seminarios de la Fundación Española de Reumatología
Ignasi Saigí Ullastre (2016)
10.1007/s00408-012-9445-1
Management of Malignant Pleural Effusion
J. Kastelik (2012)
10.1097/JTO.0b013e318200f447
The Use of Pleural Fluid sCD44v6/std Ratio for Distinguishing Mesothelioma from Other Pleural Malignancies
J. M. Porcel (2011)
10.1016/j.ejcts.2010.01.057
Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies.
H. E. Davies (2010)
10.1111/j.1440-1843.2010.01890.x
Translational advances in pleural malignancies
Georgios T. Stathopoulos (2011)
10.3978/j.issn.2072-1439.2013.04.19
The continual search for ideal biomarkers for mesothelioma: the hurdles.
F. Brims (2013)
10.1186/1471-2407-12-428
Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas
K. Sriram (2012)
10.1016/j.ccm.2012.11.002
Pleural fluid biomarkers: beyond the Light criteria.
J. M. Porcel (2013)
10.1371/journal.pone.0063873
Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells
Julius F. Varano della Vergiliana (2013)
10.1016/J.MEDCLI.2009.06.018
Diagnostic biomarkers of malignant pleural mesothelioma
JoseAntonio Rodriguez Portal (2009)
10.1097/JTO.0b013e31824c9272
CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
C. Blanquart (2012)
10.1016/j.clinbiochem.2010.05.016
Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies.
Jennifer S. Hackbarth (2010)
10.1016/J.SEMREU.2010.02.003
ABC del líquido pleural
José Manuel Porcel Pérez (2010)
10.5152/pb.2011.02
ERİŞKİNLERDEKİ TEK TARAFLI PLEVRAL EFÜZYONLARIN ARAŞTIRILMASI: BRİTANYA TORAKS DERNEĞİ PLEVRAL HASTALIKLAR KILAVUZU 2010
C. Hooper (2011)
10.1080/17476348.2020.1684266
Advances in pleural effusion diagnostics
L. Ferreiro (2019)
10.1055/s-0039-1695702
Molecular Testing on Pleural Fluid Samples.
S. Oh (2019)
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
Rosa FilibertiStefano (2013)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
10.1515/bc.2011.062
Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation
Julius F. Varano della Vergiliana (2011)
10.1097/MCP.0000000000000167
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1177/2373997515579639
Role of Mesothelin Measurement in Patients With Cytology-Negative Pleural Effusion Undergoing Medical Thoracoscopy
Su Lyn Leong (2015)
10.4046/trd.2014.76.5.211
Malignant Pleural Effusion: Medical Approaches for Diagnosis and Management
H. Nam (2014)
10.1007/S12325-010-0031-8
Management of malignant pleural effusions
Mateen H Uzbeck (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar